Prasinezumab |
Katalog-Nr.GC72383 |
Prasinezumab (PRX 002) ist ein humanisierter monoklonaler IgG1-Antikörper, der gegen aggregiertes α-Synuclein gerichtet ist.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1960462-19-4
Sample solution is provided at 25 µL, 10mM.
Prasinezumab against an epitope in the carboxyl terminus of human α-synuclein. Prasinezumab binds to human aggregated α-synuclein with a high affinity and avidity[1].
References:
[1]. Gennaro Pagano, et al. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. Front Neurol. 2021 Oct 1;12:705407.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *